For many men diagnosed with advanced prostate cancer, one of the biggest concerns is how long treatment will continue working ...

Primary Mediastinal Germ Cell Tumors: A Real-World Analysis of Clinical Characteristics, Treatment, and Survival Outcomes From Two Tertiary Cancer Centers in India Abiraterone acetate (AA) is approved ...

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved substantially over the past decade, with androgen receptor pathway inhibitors, taxanes, poly ...

The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The ...

Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...

Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...

After failure of HT, in addition to secondary hormonal manipulation (antiandrogens, ketoconazole with steroids and estrogens), these are currently the drugs approved by the US FDA for initial therapy ...

In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...

Practice-changing perioperative therapy, chemo-free combo for CSPC, reducing cognitive eff ...

In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...